Moderna, Inc.

MRNA

Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue
+29.2%
EPS
n/m
Free cash flow
n/m
Total debt
+13,550.0%

Quarter to September 2026, against a year earlier

223.37 7.98 −3.45%
Market cap
$93.6B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
3/9
ROIC
−35.1%
Net debt / EBITDA
1.8×
Payout ratio
—

Moderna, Inc. (MRNA) news

The news and the share price important stories, numbered as below

Share price since 16 October +2.5%

Stories the last two months, newest first

  1. 3 Guidance ·

    Moderna outlines 2027 cash costs of about $4 billion

    At analyst day, Moderna said it expects approximately $9 billion in year-end 2026 liquidity and around $4 billion in cash costs in 2027, with annual costs of $4 billion–$4.5 billion through 2030, largely driven by oncology investment. It is preparing manufacturing and commercialization capabilities for intismeran with Merck, pending regulatory approval, and expects gross-margin expansion of about 10 percentage points. Shares fell as investors weighed the spending against limited visibility beyond 2026.

    Reported by 6: ACCESS Newswire · InvestorsHub · MarketBeat · The Motley Fool · TIKR · Zacks

  2. 2 Product ·

    Moderna and Merck report a 42% reduction in melanoma recurrence or death risk

    In a Phase III melanoma trial, intismeran plus Keytruda reduced the risk of recurrence or death by 42% compared with Keytruda alone. Moderna and Merck are preparing a regulatory submission, with a potential approval and launch discussed for 2027. The reports also describe uncertainty around approval, manufacturing capacity, costs, patient turnaround times and commercial returns; the therapy remains unapproved.

    Reported by 4: The Motley Fool · Zacks · pharmaceutical-technology.com · TIKR

  3. Commentary ·

    Commentators weigh Moderna’s rally against valuation and execution risks

    The articles discuss Moderna’s sharp share-price gains, high valuation and reliance on newer products and pipeline candidates. They cite risks from COVID vaccine dependence, clinical and regulatory uncertainty, cash burn, debt and dilution, while noting progress in respiratory vaccines and oncology. One valuation analysis said the shares remained overvalued relative to its model, and another noted bearish options positioning ahead of the quarterly report.

    Reported by 4: TIKR · Zacks · Barchart · Simply Wall St.

  4. Other ·

    Moderna will join the MSCI World Index

    MSCI announced that Moderna will be added to the MSCI World Index as part of its November 2026 index review, effective at the close of November 30. The review also includes changes to other MSCI global, small-cap, all-cap and frontier-market indexes. The inclusion could increase Moderna’s visibility among benchmark-tracking funds.

    Reported by 2: Business Wire · Simply Wall St.

  5. 1 Results ·

    Moderna reports $1.31 billion in third-quarter revenue and raises its 2026 outlook

    Moderna reported third-quarter revenue of $1.31 billion, up 29% year over year, and net income of $162 million, returning to quarterly profitability. It raised its 2026 revenue-growth outlook to 15%–25%, reduced expected R&D spending and increased its year-end cash forecast to $8.1 billion–$8.3 billion. International COVID-19 vaccine sales contributed to growth, and the company reported positive Phase 3 melanoma results and U.S. approval of its seasonal flu vaccine.

    Reported by 33: ACCESS Newswire · Moby · The Motley Fool · GuruFocus.com · Financial Times · StockStory · Investing.com · InvestorsHub · GuruFocus.com · Proactive Investors · The Motley Fool · MT Newswires · 24/7 Wall St. · MarketBeat · TIKR · Moby · The Motley Fool · Zacks · TIKR · Investing.com · Zacks · GuruFocus.com · Simply Wall St. · Trefis · The Motley Fool · The Daily Upside · Zacks · StockStory · TIKR · TIKR · Associated Press · Zacks · The Motley Fool

  6. Product ·

    Moderna study finds lower COVID-19 risks with mNEXSPIKE than Comirnaty

    A JAMA Network Open study of 294,499 U.S. veterans aged 65 and older found mNEXSPIKE was associated with 35.9% lower risk of medically attended COVID-19 and 47% lower risk of COVID-19 hospitalization than Comirnaty. An exploratory analysis found lower risk of hospitalization involving a major adverse cardiovascular event. The observational study was supported by Moderna and had limitations, including possible residual confounding and limited generalizability.

    Reported by ACCESS Newswire

  7. Analyst ·

    Piper Sandler raises Moderna’s price target to $305

    Moderna shares rose after Piper Sandler raised its price target to $305 from $230 following a quarterly revenue beat and an improved 2026 outlook. Piper’s positive view depended heavily on Moderna’s melanoma vaccine with Merck, for which potential approval was expected in 2027. Goldman Sachs raised its target to $195 but maintained a Neutral rating, citing valuation concerns; investors were also watching upcoming kidney cancer data.

    Reported by TIKR

  8. Analyst ·

    Analysts raise Moderna fair-value estimate to $145.42

    Analysts raised Moderna’s fair-value estimate from $135.84 to $145.42 per share, citing Q3 execution and promising intismeran melanoma data. Several firms also lifted price targets, while some remained cautious about valuation and clinical risks as the company expands into additional cancers. The updated assumptions included higher revenue growth but lower net margins, a higher future P/E and a slightly higher discount rate.

    Reported by Simply Wall St.

  9. Product ·

    Canada authorizes Moderna’s flu and flu-COVID vaccines

    Health Canada authorized Moderna’s mFLUSIVA seasonal influenza vaccine and mCOFLU influenza-COVID-19 combination vaccine for adults aged 50 and older, making Canada the first country to approve both. The approvals were supported by Phase 3 trials. Moderna said it would work with Canadian authorities and immunization partners on future availability, while both products remained under review in other markets.

    Reported by 2: ACCESS Newswire · Simply Wall St.

  10. Product ·

    WHO advisers recommend Moderna’s Ebola vaccine for a Phase 2/3 study

    WHO’s Technical Advisory Group recommended Moderna’s investigational mRNA-1469 vaccine for a Phase 2/3 efficacy study in the Democratic Republic of the Congo, subject to regulatory approval. The recommendation followed encouraging preclinical results and Phase 1 data showing the vaccine was generally well tolerated and produced robust antibody responses after one dose. CEPI committed up to $58.5 million toward development and trial-dose manufacturing.

    Reported by 2: ACCESS Newswire · Simply Wall St.

  11. Product ·

    Moderna reports four responses in an early multiple myeloma trial

    In initial Phase 1/2 results for mRNA-2808, an investigational therapy encoding T-cell engagers targeting BCMA, GPRC5D and FcRH5, four of 11 evaluable, heavily pretreated patients had confirmed responses. All three engagers were detected in plasma, and no dose-limiting toxicities or treatment-related serious adverse events occurred. However, 41.7% of patients experienced Grade 3 or higher treatment-related events, predominantly hematologic.

    Reported by 2: ACCESS Newswire · TIKR

  12. Capital ·

    Moderna raises $2.6 billion through convertible notes

    Moderna expected cash and investments to decline to $4.7 billion–$5.2 billion by year-end, though it subsequently raised $2.6 billion through convertible notes. The article also lists potential catalysts including third-quarter COVID vaccine sales, possible 2026 analysis of Intismeran kidney cancer data and year-end cash results expected in February 2027. COVID vaccine sales remained central to revenue.

    Reported by Trefis

More headlines